CytomX Therapeutics, Inc. Leases Disclosure
11. Leases
Operating Lease
In December 2015, the Company entered into a lease (the “2016 Lease”) of office and laboratory space located in South San Francisco, California for the Company’s corporate headquarters. The 2016 Lease has an initial term of ten years through 2026 and the Company has an option to extend the initial term for an additional five years at the then fair rental value as determined pursuant to the 2016 Lease.
In addition, the Company obtained a standby letter of credit (the “Letter of Credit”) in an amount of approximately $0.9 million, which may be drawn by the Landlord to be applied for certain purposes upon the Company’s breach of any provisions under the 2016 Lease. The Company recorded the $0.9 million of cash securing the Letter of Credit as non-current restricted cash on its balance sheet as of December 31, 2024 and 2023. Rent expense during the years ended December 31, 2024 and 2023 was $5.1 million and $5.1 million, respectively.
Supplemental information related to leases are as follows:
|
|
Year Ended |
|
|||||
|
|
December 31, 2024 |
|
|
December 31, 2023 |
|
||
|
|
(in thousands) |
|
|||||
Cash paid for amounts included in the measurement of lease liabilities |
|
|
|
|
|
|
||
Operating cash flows from operating leases |
|
$ |
5,572 |
|
|
$ |
5,420 |
|
|
|
|
|
|
|
|
||
|
|
December 31, 2024 |
|
|
December 31, 2023 |
|
||
Weighted-average remaining lease term (in years) |
|
|
|
|
|
|
||
Operating lease |
|
1.75 |
|
|
2.75 |
|
||
Weighted-average discount rate |
|
|
|
|
|
|
||
Operating lease |
|
|
8.25 |
% |
|
|
8.25 |
% |
|
|
|
|
|
|
|
||
|
|
|
|
December 31, 2024 |
|
|
|
|
|
|
(in thousands) |
|
|
Maturity of operating lease liabilities |
|
|
|
|
|
|
2025 |
|
|
|
$ |
5,729 |
|
2026 |
|
|
|
|
4,387 |
|
Total lease payments |
|
|
|
|
10,116 |
|
Less imputed interest |
|
|
|
|
(731 |
) |
Present value of lease liabilities |
|
|
|
$ |
9,385 |
|
In March 2023, the Company entered into a sublease agreement for a portion of its existing office and laboratory space. The sublease is classified as an operating lease whereby sublease income is recognized on a straight-line basis over the sublease term that expires on September 30, 2026. For the year ended December 31, 2024 and 2023, sublease income was $1.2 million and $0.9 million, respectively.
|
|
December 31, 2024 |
|
|
|
|
(in thousands) |
|
|
Future sublease income payments |
|
|
|
|
2025 |
|
|
1,379 |
|
2026 |
|
|
1,067 |
|
Total sublease income payments |
|
$ |
2,446 |
|
Want the next CytomX Therapeutics, Inc. leases disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment CytomX Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.